Laboratory Medicine ›› 2016, Vol. 31 ›› Issue (12): 1081-1086.DOI: 10.3969/j.issn.1673-8640.2016.12.016
• Orginal Article • Previous Articles Next Articles
KANG Juan
Received:2016-01-09
Online:2016-12-25
Published:2016-12-29
CLC Number:
KANG Juan. Introduction on protein value-transfer procedure using cystatin C as an example[J]. Laboratory Medicine, 2016, 31(12): 1081-1086.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2016.12.016
| 项目 | R1 | R2 | R3* | R4* | R5* | R6* |
|---|---|---|---|---|---|---|
| ERM-DA471(g) | 0.200 0 | 0.500 0 | 0.390 0(R2) | 0.300 0(R3) | 0.200 0(R4) | 0.100 0(R5) |
| 稀释缓冲液(g) | 0.000 0 | 0.125 0 | 0.130 0 | 0.150 0 | 0.200 0 | 0.100 0 |
| 稀释因子 | 1.000 0 | 0.800 0 | 0.750 0 | 0.666 7 | 0.500 0 | 0.500 0 |
| 预稀释因子 | 1.000 0 | 1.000 0 | 0.800 0 | 0.600 0 | 0.400 0 | 0.200 0 |
| 理论相对浓度(%) | 100.00 | 80.00 | 60.00 | 40.00 | 20.00 | 10.00 |
| 项目 | R1 | R2 | R3* | R4* | R5* | R6* |
|---|---|---|---|---|---|---|
| ERM-DA471(g) | 0.200 0 | 0.500 0 | 0.390 0(R2) | 0.300 0(R3) | 0.200 0(R4) | 0.100 0(R5) |
| 稀释缓冲液(g) | 0.000 0 | 0.125 0 | 0.130 0 | 0.150 0 | 0.200 0 | 0.100 0 |
| 稀释因子 | 1.000 0 | 0.800 0 | 0.750 0 | 0.666 7 | 0.500 0 | 0.500 0 |
| 预稀释因子 | 1.000 0 | 1.000 0 | 0.800 0 | 0.600 0 | 0.400 0 | 0.200 0 |
| 理论相对浓度(%) | 100.00 | 80.00 | 60.00 | 40.00 | 20.00 | 10.00 |
| 项目 | T1 | T2 | T3* | T4* | T5* | T6* |
|---|---|---|---|---|---|---|
| 候选标准物质(g) | 0.300 0 | 0.660 0 | 0.510 0(T2) | 0.360 0(T3) | 0.240 0(T4) | 0.150 0(T5) |
| 稀释缓冲液(g) | 0.000 0 | 0.165 0 | 0.170 0 | 0.180 0 | 0.240 0 | 0.150 0 |
| 稀释因子 | 1.000 0 | 0.800 0 | 0.750 0 | 0.666 7 | 0.500 0 | 0.500 0 |
| 预稀释因子 | 1.000 0 | 1.000 0 | 0.800 0 | 0.600 0 | 0.400 0 | 0.200 0 |
| 理论相对浓度(%) | 100.00 | 80.00 | 60.00 | 40.00 | 20.00 | 10.00 |
| 项目 | T1 | T2 | T3* | T4* | T5* | T6* |
|---|---|---|---|---|---|---|
| 候选标准物质(g) | 0.300 0 | 0.660 0 | 0.510 0(T2) | 0.360 0(T3) | 0.240 0(T4) | 0.150 0(T5) |
| 稀释缓冲液(g) | 0.000 0 | 0.165 0 | 0.170 0 | 0.180 0 | 0.240 0 | 0.150 0 |
| 稀释因子 | 1.000 0 | 0.800 0 | 0.750 0 | 0.666 7 | 0.500 0 | 0.500 0 |
| 预稀释因子 | 1.000 0 | 1.000 0 | 0.800 0 | 0.600 0 | 0.400 0 | 0.200 0 |
| 理论相对浓度(%) | 100.00 | 80.00 | 60.00 | 40.00 | 20.00 | 10.00 |
| 项目 | R1 | R2 | R3* | R4* | R5* | R6* |
|---|---|---|---|---|---|---|
| ERM-DA471(g)# | 0.200 0 | 0.517 4 | 0.389 2(R2) | 0.296 7(R3) | 0.206 8(R4) | 0.101 0(R5) |
| 稀释缓冲液(g) | 0.000 0 | 0.123 0 | 0.128 9 | 0.149 4 | 0.198 8 | 0.099 5 |
| 稀释因子 | 1.000 0 | 0.807 9 | 0.751 2 | 0.665 1 | 0.509 9 | 0.503 7 |
| 预稀释因子 | 1.000 0 | 1.000 0 | 0.807 9 | 0.606 9 | 0.403 7 | 0.205 8 |
| 理论相对浓度(%) | 100.0 | 80.79 | 60.69 | 40.37 | 20.58 | 10.37 |
| 项目 | R1 | R2 | R3* | R4* | R5* | R6* |
|---|---|---|---|---|---|---|
| ERM-DA471(g)# | 0.200 0 | 0.517 4 | 0.389 2(R2) | 0.296 7(R3) | 0.206 8(R4) | 0.101 0(R5) |
| 稀释缓冲液(g) | 0.000 0 | 0.123 0 | 0.128 9 | 0.149 4 | 0.198 8 | 0.099 5 |
| 稀释因子 | 1.000 0 | 0.807 9 | 0.751 2 | 0.665 1 | 0.509 9 | 0.503 7 |
| 预稀释因子 | 1.000 0 | 1.000 0 | 0.807 9 | 0.606 9 | 0.403 7 | 0.205 8 |
| 理论相对浓度(%) | 100.0 | 80.79 | 60.69 | 40.37 | 20.58 | 10.37 |
| 项目 | T1 | T2 | T3* | T4* | T5* | T6* |
|---|---|---|---|---|---|---|
| 候选标准物质(g) | 0.300 0 | 0.667 1 | 0.514 5(T2) | 0.363 8(T3) | 0.222 5(T4) | 0.151 4(T5) |
| 稀释缓冲液(g) | 0.000 0 | 0.163 0 | 0.169 0 | 0.179 4 | 0.235 4 | 0.150 1 |
| 稀释因子 | 1.000 0 | 0.803 6 | 0.752 7 | 0.669 7 | 0.485 9 | 0.502 2 |
| 预稀释因子 | 1.000 0 | 1.000 0 | 0.803 6 | 0.604 9 | 0.405 1 | 0.196 9 |
| 理论相对浓度(%) | 100.0 | 80.36 | 60.49 | 40.51 | 19.69 | 9.886 |
| 项目 | T1 | T2 | T3* | T4* | T5* | T6* |
|---|---|---|---|---|---|---|
| 候选标准物质(g) | 0.300 0 | 0.667 1 | 0.514 5(T2) | 0.363 8(T3) | 0.222 5(T4) | 0.151 4(T5) |
| 稀释缓冲液(g) | 0.000 0 | 0.163 0 | 0.169 0 | 0.179 4 | 0.235 4 | 0.150 1 |
| 稀释因子 | 1.000 0 | 0.803 6 | 0.752 7 | 0.669 7 | 0.485 9 | 0.502 2 |
| 预稀释因子 | 1.000 0 | 1.000 0 | 0.803 6 | 0.604 9 | 0.405 1 | 0.196 9 |
| 理论相对浓度(%) | 100.0 | 80.36 | 60.49 | 40.51 | 19.69 | 9.886 |
| 测试结果 | T1 | T2 | T3 | T4 | T5 | T6 | C |
|---|---|---|---|---|---|---|---|
| 第1个循环 | |||||||
| 第1次测试 | 80.76 | 64.59 | 48.24 | 32.21 | 16.49 | 10.37 | 50.49 |
| 第2次测试 | 81.56 | 65.03 | 48.24 | 32.24 | 16.49 | 10.37 | 50.93 |
| 均值 | 81.16 | 64.81 | 48.24 | 32.23 | 16.49 | 10.37 | 50.71 |
| 第2个循环 | |||||||
| 第1次测试 | 80.81 | 64.43 | 47.85 | 32.54 | 16.63 | 10.37 | 51.24 |
| 第2次测试 | 81.19 | 64.38 | 48.32 | 32.32 | 16.48 | 10.37 | 50.86 |
| 均值 | 81.00 | 64.41 | 48.09 | 32.43 | 16.56 | 10.37 | 51.05 |
| 第3个循环 | |||||||
| 第1次测试 | 82.22 | 64.67 | 46.31 | 31.37 | 16.85 | 11.49 | 50.10 |
| 第2次测试 | 81.57 | 64.64 | 47.03 | 30.79 | 17.10 | 10.96 | 49.99 |
| 均值 | 81.90 | 64.66 | 46.67 | 31.08 | 16.98 | 11.23 | 50.05 |
| 总均值(Y)* | 81.35 | 64.62 | 47.67 | 31.91 | 16.67 | 10.66 | 50.60 |
| Y-3s | 79.92 | 64.01 | 45.07 | 29.73 | 15.88 | 9.17 | 49.07 |
| Y+3s | 82.78 | 65.24 | 50.26 | 34.09 | 17.46 | 12.14 | 52.14 |
| 测试结果 | T1 | T2 | T3 | T4 | T5 | T6 | C |
|---|---|---|---|---|---|---|---|
| 第1个循环 | |||||||
| 第1次测试 | 80.76 | 64.59 | 48.24 | 32.21 | 16.49 | 10.37 | 50.49 |
| 第2次测试 | 81.56 | 65.03 | 48.24 | 32.24 | 16.49 | 10.37 | 50.93 |
| 均值 | 81.16 | 64.81 | 48.24 | 32.23 | 16.49 | 10.37 | 50.71 |
| 第2个循环 | |||||||
| 第1次测试 | 80.81 | 64.43 | 47.85 | 32.54 | 16.63 | 10.37 | 51.24 |
| 第2次测试 | 81.19 | 64.38 | 48.32 | 32.32 | 16.48 | 10.37 | 50.86 |
| 均值 | 81.00 | 64.41 | 48.09 | 32.43 | 16.56 | 10.37 | 51.05 |
| 第3个循环 | |||||||
| 第1次测试 | 82.22 | 64.67 | 46.31 | 31.37 | 16.85 | 11.49 | 50.10 |
| 第2次测试 | 81.57 | 64.64 | 47.03 | 30.79 | 17.10 | 10.96 | 49.99 |
| 均值 | 81.90 | 64.66 | 46.67 | 31.08 | 16.98 | 11.23 | 50.05 |
| 总均值(Y)* | 81.35 | 64.62 | 47.67 | 31.91 | 16.67 | 10.66 | 50.60 |
| Y-3s | 79.92 | 64.01 | 45.07 | 29.73 | 15.88 | 9.17 | 49.07 |
| Y+3s | 82.78 | 65.24 | 50.26 | 34.09 | 17.46 | 12.14 | 52.14 |
| 检测方法 | 第1组 | 第2组 | 第3组 | 第4组 | 均值(mg/L) | CV(%) |
|---|---|---|---|---|---|---|
| PETIA | 4.35 | 4.40 | 4.43 | 4.47 | 4.41 | 1.3 |
| PENIA | 4.47 | 4.60 | 4.46 | 4.54 | 4.52 | 1.5 |
| 检测方法 | 第1组 | 第2组 | 第3组 | 第4组 | 均值(mg/L) | CV(%) |
|---|---|---|---|---|---|---|
| PETIA | 4.35 | 4.40 | 4.43 | 4.47 | 4.41 | 1.3 |
| PENIA | 4.47 | 4.60 | 4.46 | 4.54 | 4.52 | 1.5 |
| 1 | JOHNSON AM,WHICHER JT,LEDUE TB,et al. Effect of a new international reference preparation for proteins in human serum(certified reference material 470) on results of the College of American Pathologists Surveys for plasma proteins[J]. Arch Pathol Lab Med,2000,124(10):1496-1501. |
| 2 | JOHNSON AM,WHICHER JT. Effect of certified reference material 470(CRM 470) on national quality assurance programs for serum proteins in Europe[J]. Clin Chem Lab Med,2001,39(11):1123-1128. |
| 3 | 唐文佳,吴炯. 特定蛋白检测标准化——从CRM 470到ERM-DA470k及ERM-DA472k[J]. 检验医学,2012,27(4):237-242. |
| 4 | BLIRUP-JENSEN S. Protein standardization Ⅰ:protein purification procedure for the purification of human prealbumin,orosomucoid and transferrin as primary protein preparations[J]. Clin Chem Lab Med,2001,39(11):1076-1089. |
| 5 | BLIRUP-JENSEN S. Protein standardization Ⅱ:dry mass determination procedure for the determination of the dry mass of a pure protein preparation[J]. Clin Chem Lab Med,2001,39(11):1090-1097. |
| 6 | BLIRUP-JENSEN S. Protein standardization Ⅲ:method optimization basic principles for quantitative determination of human serum proteins on automated instruments based on turbidimetry or nephelometry[J]. Clin Chem Lab Med,2001,39(11):1098-1109. |
| 7 | BLIRUP-JENSEN S,JOHNSON AM,LARSEN M. Protein standardization Ⅳ:value transfer procedure for the assignment of serum protein values from a reference preparation to a target material[J]. Clin Chem Lab Med,2001,39(11):1110-1122. |
| 8 | BLIRUP-JENSEN S,JOHNSON AM,LARSEN M,et al. Protein standardization Ⅴ:value transfer. A practical protocol for the assignment of serum protein values from a reference material to a target material[J]. Clin Chem Lab Med,2008,46(10):1470-1479. |
| 9 | REIMER CB,SMITH SJ,WELLS TW,et al. Collaborative calibration of the U.S. National and the College of American Pathologists reference preparation for specific serum proteins[J]. Am J Clin Pathol,1982,77(1):12-19. |
| 10 | THOLEN DW,HOMBURGER HA. Assigning concentration estimates for the CAP reference preparation for serum proteins[J]. Pathologist,1984,38:226-228. |
| 11 | FINNEY DJ.Statistical methods in biological assay[M]. 3rd ed. New York:MacMillan,1978:69-1104. |
| 12 | REIMER CB,SMITH SF,HANNON WH,et al. Progress towards international reference standards for human serum proteins[J]. J Biol Stand,1978,6(2):133-158. |
| 13 | GRUBB A,BLIRUP-JENSEN S,LINDSTRM V,et al. First certified reference material for cystatin C in human serum ERM-DA471/IFCC[J]. Clin Chem Lab Med,2010,48(11):1619-1621. |
| 14 | GRUBB A,HORIO M,HANSSON LO,et al. Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator[J]. Clin Chem,2014,60(7):974-986. |
| 15 | 国秀芝,吴洁,侯立安,等. 五种可溯源胱抑素C检测系统结果的一致性评价[J]. 中华检验医学杂志,2014,37(5):365-370. |
| 16 | 康娟,王军,李彦超,等. 胱抑素C国家标准物质的研制[J]. 中华检验医学杂志,2013,36(10):942-946. |
| 17 | 张传宝,赵海建,曾洁,等. 胱抑素C标准物质ERM-DA 471/IFCC的互通性研究[J].中华检验医学杂志,2015,38(5):306-309. |
| [1] | YAO Yan, GU Juxian, LI Meng, LI Guoce, AI Jingyi, ZHAO Li. Diagnostic roles of transforming growth factor-beta-activated kinase 1 and autophagy-related protein 7 in cerebrospinal fluid of patients with tuberculous meningitis [J]. Laboratory Medicine, 2025, 40(9): 829-833. |
| [2] | CHU Ye, XIONG Chunxiang, HUANG Yu, ZENG Jiaxing, YI Bode, HUANG Nenggan, YANG Yifeng, YANG Feng. Role of nomogram models based on CAR and NLR in predicting 1-year mortality in elderly patients with hip fractures after surgery [J]. Laboratory Medicine, 2025, 40(9): 834-840. |
| [3] | LIU Hao, FU Miao, LIU Peng, TIAN Wen, WANG Sha, YIN Xiaomei, WANG Donghai. Expressions and roles of WDR5 and miR-455-5p in cervical cancer patients [J]. Laboratory Medicine, 2025, 40(9): 867-874. |
| [4] | WANG Chunhong. Relationship between sd-LDL-C/HDL-C and short-term prognosis of percutaneous coronary intervention in patients with acute myocardial infarction [J]. Laboratory Medicine, 2025, 40(9): 875-880. |
| [5] | CAO Yue, SUN Qijuan, WANG Su, PAN Yiru, WANG Shiwen. Reference range of serum cystatin C in elders in Shanghai [J]. Laboratory Medicine, 2025, 40(8): 731-734. |
| [6] | SUN Yang, LI Shouxia, CAI Huixin. Correlation between serum sd-LDL-C and AIP and the severity of coronary heart disease [J]. Laboratory Medicine, 2025, 40(8): 757-762. |
| [7] | WU Jun, TAO Yue, CHEN Dezhu, SHA Jiaojiao, DU Liangjia, CHEN Yiqiang, LIU Siyuan, SONG Hongyan, ZHENG Qian, BAI Bing. Positive rate analysis of urinary AD7c-NTP of patients with different brain diseases [J]. Laboratory Medicine, 2025, 40(7): 642-647. |
| [8] | YAN Hua, GAO Dahan, LIU Dongfeng. Correlation and clinical significance of serum lncRNA THRIL and miR-495-3p expressions with common intestinal bacterial species in children with inflammatory bowel disease [J]. Laboratory Medicine, 2025, 40(6): 565-570. |
| [9] | YIN Liangping, YUAN Yongming, QU Bin, LI Wenna, ZHANG Shu. Role of neutrophil CD64 absolute value determined by cell solid-phase chip method in bacterial infectious disease diagnosis [J]. Laboratory Medicine, 2025, 40(6): 571-575. |
| [10] | YAO Ling, GAO Chunyan, LIU Minglei. Virulence characteristics of Streptococcus pneumoniae,PBP gene mutation and β-lactam resistance [J]. Laboratory Medicine, 2025, 40(5): 450-454. |
| [11] | LI Yazhou, SU Min, ZHANG Jinghao, FANG Yi, WANG Su, WANG Shiwen, ZHAO Hu. Roles of single and combined determinations of CRP,HBP,CLR and HAR in the diagnosis of bloodstream infection in elderly patients [J]. Laboratory Medicine, 2025, 40(5): 489-492. |
| [12] | SUN Haiqing, LIU Ning, LOU Jinli, YU Yanhua. Clinical role of STIP1 and AFP-L3 combined determination in diagnosing HCC [J]. Laboratory Medicine, 2025, 40(4): 324-330. |
| [13] | ZHU Jing, ZHANG Rulin, WU Jun. Expressions of CCNB1,PTTG1 and CBX3 in hepatocellular carcinoma and their roles in prognostic assessment [J]. Laboratory Medicine, 2025, 40(4): 331-337. |
| [14] | CHEN Weilong, WANG Yongbing, CHEN Zegang. Correlation between ZBED3,CYFRA21-1,VEGF and short-term mortality risk in patients with advanced liver cancer [J]. Laboratory Medicine, 2025, 40(4): 338-343. |
| [15] | GUI Jing, WANG Feng, CAI Yumao, HONG Chuangyue, YANG Hui. Correlation between oxidized high-density lipoprotein and comorbidity of T2DM and PTB [J]. Laboratory Medicine, 2025, 40(4): 350-357. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||